Breaking News, Trials & Filings

Icon Expands Early Phase Capabilities

Opens new Clinical Research Unit and satellite outpatient clinics.

Author Image

By: Charlie Sternberg

Associate Editor

Icon plc, a clinical research organization, is expanding its early phase capabilities with the opening of a new Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will expand Icon’s capacity to conduct first-in-human, healthy participant, and patient cohort studies.

A key feature of the new San Antonio CRU is its fully integrated infrastructure. The clinic, pharmacy, laboratory, and investigational product handling are co-located. Onsite capabilities include a Good Manufacturing Practice/Good Clinical Practice (GMP/GCP) compliant pharmacy and manufacturing space with International Organization for Standardization (ISO) cleanrooms, a clinical safety laboratory, and sample processing and shipping facilities.

This new facility has also been designed with participant comfort, safety, and experience as a priority. It features private and semi-private dormitories, recreation areas, dedicated clinical spaces, and advanced safety systems for continuous monitoring and rapid clinical response.

“We’ve designed the clinic to improve the experience of study participants, while scaling our capacity and maintaining our high-quality standards,” said Dr. Ute Berger, Icon’s Chief Medical Officer and President, Development Solutions. “By fully integrating our clinical, laboratory, and pharmacy operations under one roof, we can largely eliminate logistical delays. This translates directly into faster dosing, real-time adaptability, and accelerated delivery of high-quality data for our sponsors.”

In addition to the San Antonio clinic, Icon’s two new satellite outpatient facilities in Houston, Texas, and Lawrence, Kansas will further expand recruitment reach for its existing CRUs in the region. They will also provide greater flexibility for studies requiring extended Phase I follow-up, bringing care closer to participants and reducing travel burden.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics